GarnickM.B.: Prostate cancer: screening, diagnosis, and management. Ann Int Med, 118: 804–818, 1993.
2.
TakayamaT.K., VessellaR.L., LangeP.H.: Newer applications of serum prostate-specific antigen in the management of prostate cancer. Semin Oncol, 21: 542–553, 1994.
3.
PoundC.R., PartinA.W., EisenbergerM.A.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591–1597, 1999.
4.
RuckleH.C., KleeG.G., OesterlingJ.E.: Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clinic Proceedings, 69: 69–79, 1994.
5.
EisenbergerM.A., BlumensteinB.A., CrawfordE.D.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med, 339: 1036–1042, 1998.
6.
Prostate Cancer Trialists’ Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet, 355: 1491–1498, 2000.
7.
SmallE.J., VogelzangN.J.: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol, 5: 382–388, 1997.
8.
ScherH.I., KellyW.K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol, 11: 1566–1572, 1993.
9.
MyersC., CooperM., SteinC.: Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol, 10: 881–889, 1992.
10.
TannockI.F., OsobaD., StockierM.R.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol, 14: 1756–1764, 1996.
